I dont believe a SPP is on the cards at all. I doubt any SPP can raise the amount of funds POH require to fund the Oxy Phase 2 trials and launch of cellucreme plus company operations going forward. An insto placement is the obvious plan A to me- clean and quick to arrange. (Orbis alone may well be enthusiastic to fund this given their existing exposure.) Otherwise there are plenty of instos that are plentiful on other Aussie Biotech registries that POH can tap for funds. What do others think here?
KC
financials have been released, page-16
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.507M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 47 | 86502619 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 59770911 | 19 |
View Market Depth
| Last trade - 11.46am 21/08/2024 (20 minute delay) ? |
| AVE (ASX) Chart |
Day chart unavailable